111 related articles for article (PubMed ID: 6825112)
1. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
Jordan VC; Bain RR; Brown RR; Gosden B; Santos MA
Cancer Res; 1983 Mar; 43(3):1446-50. PubMed ID: 6825112
[TBL] [Abstract][Full Text] [Related]
2. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
[TBL] [Abstract][Full Text] [Related]
3. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
Lien EA; Wester K; Lønning PE; Solheim E; Ueland PM
Br J Cancer; 1991 Apr; 63(4):641-5. PubMed ID: 2021551
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Jordan VC; Gosden B
Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
[TBL] [Abstract][Full Text] [Related]
5. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
6. Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.
Jordan VC
Breast Cancer Res Treat; 1982; 2(2):123-38. PubMed ID: 6184101
[TBL] [Abstract][Full Text] [Related]
7. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
Fabian C; Tilzer L; Sternson L
Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
[TBL] [Abstract][Full Text] [Related]
8. Determination of tamoxifen and metabolites in human serum by high-performance liquid chromatography with post-column fluorescence activation.
Brown RR; Bain R; Jordan VC
J Chromatogr; 1983 Feb; 272(2):351-8. PubMed ID: 6833432
[TBL] [Abstract][Full Text] [Related]
9. Identification and biological activity of tamoxifen metabolites in human serum.
Kemp JV; Adam HK; Wakeling AE; Slater R
Biochem Pharmacol; 1983 Jul; 32(13):2045-52. PubMed ID: 6870933
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
11. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
[TBL] [Abstract][Full Text] [Related]
12. Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen.
Dix CJ; Jordan VC
Endocrinology; 1980 Dec; 107(6):2011-20. PubMed ID: 7191796
[TBL] [Abstract][Full Text] [Related]
13. Determination of tamoxifen and an hydroxylated metabolite in plasma from patients with advanced breast cancer using gas chromatography-mass spectrometry.
Daniel CP; Gaskell SJ; Bishop H; Nicholson RI
J Endocrinol; 1979 Dec; 83(3):401-8. PubMed ID: 536670
[TBL] [Abstract][Full Text] [Related]
14. Analysis of tamoxifen and its metabolites in human plasma by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
Murphy C; Fotsis T; Pantzar P; Adlercreutz H; Martin F
J Steroid Biochem; 1987 May; 26(5):547-55. PubMed ID: 3586671
[TBL] [Abstract][Full Text] [Related]
15. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P; Ribeiro G; Adam H; Patterson J
Cancer Chemother Pharmacol; 1980; 5(2):109-11. PubMed ID: 7471314
[TBL] [Abstract][Full Text] [Related]
16. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
17. An ultra performance liquid chromatography-tandem MS assay for tamoxifen metabolites profiling in plasma: first evidence of 4'-hydroxylated metabolites in breast cancer patients.
Dahmane E; Mercier T; Zanolari B; Cruchon S; Guignard N; Buclin T; Leyvraz S; Zaman K; Csajka C; Decosterd LA
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Dec; 878(32):3402-14. PubMed ID: 21094101
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
[TBL] [Abstract][Full Text] [Related]
19. Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer.
Toko T; Shibata J; Nukatsuka M; Yamada Y
Cancer Chemother Pharmacol; 1997; 39(5):390-8. PubMed ID: 9054952
[TBL] [Abstract][Full Text] [Related]
20. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Kisanga ER; Gjerde J; Guerrieri-Gonzaga A; Pigatto F; Pesci-Feltri A; Robertson C; Serrano D; Pelosi G; Decensi A; Lien EA
Clin Cancer Res; 2004 Apr; 10(7):2336-43. PubMed ID: 15073109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
